Wvaccination with the secreted glycoprotein G of herpes simplex virus 2 induces protective immunity after genital infection

Viruses

Volumn 8, Issue 4, 2016, Pages

  Önnheim, Karin ^a   Ekblad, Maria ^a   Görander, Staffan ^a   Bergström, Tomas ^a   Liljeqvist, Jan Åke ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Herpes simplex virus 2; Secreted glycoprotein G; Vaccination

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; MEDROXYPROGESTERONE ACETATE; THROMBOSPONDIN; GLYCOPROTEIN; HERPES SIMPLEX VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; US4 PROTEIN, HUMAN HERPESVIRUS 2; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENE SEQUENCE; GENITAL TRACT INFECTION; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; VACCINATION; VAGINAL SECRETION; VIRUS LOAD; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; CHLOROCEBUS AETHIOPS; DISEASE MODEL; HERPES GENITALIS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; IMMUNIZATION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; T-LYMPHOCYTES; VIRAL LOAD; VIRAL PROTEINS;

EID: 84964545041     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v8040110     Document Type: Article

References (42)

1. Langenberg, A.G.; Corey, L.; Ashley, R.L.; Leong, W.P.; Straus, S.E. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV vaccine study group. N. Engl. J. Med. 1999, 341, 1432-1438. [CrossRef] [PubMed]
2. Mertz, G.J.; Benedetti, J.; Ashley, R.; Selke, S.A.; Corey, L. Risk factors for the sexual transmisson of genital herpes. Ann. Int. Med. 1992, 116, 197-202.[CrossRef] [PubMed]
3. Schiffer, J.T.; Corey, L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat. Med. 2013, 19, 280-290.[CrossRef] [PubMed]
4. Looker, K.J.; Magaret, A.S.; Turner, K.M.; Vickerman, P.; Gottlieb, S.L.; Newman, L.M. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE 2015, 10, e114989. [CrossRef] [PubMed]
5. Freeman, E.E.; Weiss, H.A.; Glynn, J.R.; Cross, P.L.; Whitworth, J.A.; Hayes, R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. Aids 2006, 20, 73-83.[CrossRef] [PubMed]
6. Belshe, R.B.; Leone, P.A.; Bernstein, D.I.; Wald, A.; Levin, M.J.; Stapleton, J.T.; Gorfinkel, I.; Morrow, R.L.; Ewell, M.G.; Stokes-Riner, A. et al. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 2012, 366, 34-43. [CrossRef] [PubMed]
7. Corey, L.; Langenberg, A.G.; Ashley, R.; Sekulovich, R.E.; Izu, A.E.; Douglas, J.M., Jr.; Handsfield, H.H.; Warren, T.; Marr, L.; Tyring, S. et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV vaccine study group. JAMA 1999, 282, 331-340.[CrossRef] [PubMed]
8. Su, H.K.; Eberle, R.; Courtney, R.J. Processing of the herpes simplex virus type 2 glycoprotein gG-2 results in secretion of a 34,000 mr cleavage product. J. Virol. 1987, 61, 1735-1737.[PubMed]
9. Balachandran, N.; Hutt-Fletcher, L.M. Synthesis and processing of glycoprotein gG of herpes simplex virus type 2. J. Virol. 1985, 54, 825-832.[PubMed]
10. Olofsson, S.; Lundström, M.; Marsden, H.; Jeansson, S.; Vahlne, A. Characterization of a herpes simplex virus type 2-specified glycoprotein with affinity for N-acetylgalactosamine-specific lectins and its identification as g92k or gG. J. Gen. Virol. 1986, 67, 737-744. [CrossRef] [PubMed]
11. McGeoch, D.J.; Moss, H.W.M.; McNab, D.; Frame, M.C. DNA sequence and genetic content of the HindIII l region in the short unique component of the herpes simplex virus type 2 genome: Identification of the gene encoding glycoprotein G, and evolutionary comparisons. J. Gen. Virol. 1987, 68, 19-38.[CrossRef] [PubMed]
12. Ashley, R.L.; Militoni, J.; Lee, F.; Nahmias, A.; Corey, L. Comparison of western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus type 1 and 2 in human sera. J. Clin. Microbiol. 1988, 26, 662-667.[PubMed]
13. Görander, S.; Svennerholm, B.; Liljeqvist, J.-Å. The secreted portion of glycoprotein G of herpes simplex virus type 2 is a novel antigen for type-discriminating serology. J. Clin. Microbiol. 2003, 41, 3681-3686.[CrossRef] [PubMed]
14. Lee, F.K.; Coleman, M.; Pereira, L.; Bailey, P.D.; Tatsuno, M.; Nahmias, A.J. Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J. Clin. Microbiol. 1985, 22, 641-644.[PubMed]
15. Svennerholm, B.; Olofsson, S.; Jeansson, S.; Vahlne, A.; Lycke, E. Herpes simplex virus type-selective enzyme-linked immunosorbent assay with Helix pomatia lectin-purified antigens. J. Clin. Microbiol. 1984, 19, 235-239.[PubMed]
16. Carmack, M.A.; Yasukawa, L.L.; Chang, S.Y.; Tran, C.; Saldana, F.; Arvin, A.M.; Prober, C.G. T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2. J. Infect. Dis. 1996, 174, 899-906.[CrossRef] [PubMed]
17. Eriksson, K.; Bellner, L.; Görander, S.; Löwhagen, G.-B.; Tunbäck, P.; Rydberg, K.; Liljeqvist, J.-Å. CD4+ T-cell responses to herpes simplex virus type 2 (HSV-2) glycoprotein G are type specific and differ in symptomatic and asymptomatic HSV-2-infected individuals. J. Gen. Virol. 2004, 85, 2139-2147.[CrossRef] [PubMed]
18. Ho, D.W.T.; Field, P.R.; Sjögren-Jansson, E.; Jeansson, S.; Cunningham, A.L. Indirect ELISA for the detection of HSV-2 specific IgG and IgM antibodies with glycoprotein G (gG-2). J. Virol. Methods 1992, 36, 249-264.[CrossRef]
19. Ashley, R.L. Genital herpes. Type-specific antibodies for diagnosis and management. Dermatol. Clin. 1998, 16, 789-793.[CrossRef]
20. Adamiak, B.; Ekblad, M.; Bergstrom, T.; Ferro, V.; Trybala, E. Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo-and polysaccharide inhibitors of virus attachment to cells. J. Virol. 2007, 81, 13424-13434.[CrossRef] [PubMed]
21. Bellner, L.; Thoren, F.; Nygren, E.; Liljeqvist, J.A.; Karlsson, A.; Eriksson, K. A proinflammatory peptide from herpes simplex virus type 2 glycoprotein G affects neutrophil, monocyte, and NK cell functions. J. Immunol. 2005, 174, 2235-2241.[CrossRef] [PubMed]
22. Viejo-Borbolla, A.; Martinez-Martin, N.; Nel, H.J.; Rueda, P.; Martin, R.; Blanco, S.; Arenzana-Seisdedos, F.; Thelen, M.; Fallon, P.G.; Alcami, A. Enhancement of chemokine function as an immunomodulatory strategy employed by human herpesviruses. PLoS Pathog. 2012, 8, 423-428.[CrossRef] [PubMed]
23. Martinez-Martin, N.; Viejo-Borbolla, A.; Martin, R.; Blanco, S.; Benovic, J.L.; Thelen, M.; Alcami, A. Herpes simplex virus enhances chemokine function through modulation of receptor trafficking and oligomerization. Nat. Commun. 2015, 6, 6163.[CrossRef] [PubMed]
24. Cabrera, J.R.; Viejo-Borbolla, A.; Martinez-Martin, N.; Blanco, S.; Wandosell, F.; Alcami, A. Secreted herpes simplex virus-2 glycoprotein G modifies NGF-TrkA signaling to attract free nerve endings to the site of infection. PLoS Pathog. 2015, 11, e1004571.[CrossRef] [PubMed]
25. Liljeqvist, J.A.; Trybala, E.; Hoebeke, J.; Svennerholm, B.; Bergstrom, T. Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants. J. Gen. Virol. 2002, 83, 157-165.[CrossRef] [PubMed]
26. Liljeqvist, J.-Å.; Trybala, E.; Svennerholm, B.; Jeansson, S.; Sjögren-Jansson, E.; Bergström, T. Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies. J. Gen. Virol. 1998, 79, 1215-1224.[CrossRef] [PubMed]
27. Bergström, T.; Sjögren-Jansson, E.; Jeansson, S.; Lycke, E. Mapping neuroinvasiveness of the herpes simplex virus type 1 encephalitis-inducing strain 2762 by the use of monoclonal antibodies. Mol. Cell. Probes 1992, 6, 41-49.[CrossRef]
28. Gorander, S.; Ekblad, M.; Bergstrom, T.; Liljeqvist, J.A. Anti-glycoprotein G antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Viruses 2014, 6, 4358-4372.[CrossRef] [PubMed]
29. Görander, S.; Lindqvist, M.; Harandi, A.; Bergström, T.; Liljeqvist, J.-A. Glycoprotein G of herpes simplex virus type 2 as a novel vaccine antigen for immunity to genital and neurological disease. J. Virol. 2012, 86, 7544-7553.[CrossRef] [PubMed]
30. Davis, H.L.; Weeratna, R.; Waldschmidt, T.J.; Tygrett, L.; Schorr, J.; Krieg, A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 1998, 160, 870-876.[PubMed]
31. Visciano, M.L.; Tagliamonte, M.; Tornesello, M.L.; Buonaguro, F.M.; Buonaguro, L. Effects of adjuvants on IgG subclasses elicited by virus-like particles. J. Transl. Med. 2012, 10, 1-9.[CrossRef] [PubMed]
32. Harandi, A.M.; Svennerholm, B.; Holmgren, J.; Eriksson, K. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J. Virol. 2001, 75, 6705-6709.[CrossRef] [PubMed]
33. Harandi, A.M.; Svennerholm, B.; Holmgren, J.; Eriksson, K. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 2001, 82, 845-853.[CrossRef] [PubMed]
34. Milligan, G.N.; Bernstein, D.I.; Bourne, N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 1998, 160, 6093-6100.[PubMed]
35. Iijima, N.; Linehan, M.M.; Zamora, M.; Butkus, D.; Dunn, R.; Kehry, M.R.; Laufer, T.M.; Iwasaki, A. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J. Exp. Med. 2008, 205, 3041-3052.[CrossRef] [PubMed]
36. Parr, M.B.; Parr, E.L. Vaginal immunity in the HSV-2 mouse model. Int. Rev. Immunol. 2003, 22, 43-63.[CrossRef] [PubMed]
37. Milligan, G.N.; Bernstein, D.I. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997, 229, 259-268.[CrossRef] [PubMed]
38. Belshe, R.B.; Heineman, T.C.; Bernstein, D.I.; Bellamy, A.R.; Ewell, M.; van der Most, R.; Deal, C.D. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J. Infect. Dis. 2014, 209, 828-836.[CrossRef] [PubMed]
39. Awasthi, S.; Belshe, R.B.; Friedman, H.M. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. J. Infect. Dis. 2014, 210, 571-575.[CrossRef] [PubMed]
40. Petro, C.; Gonzalez, P.A.; Cheshenko, N.; Jandl, T.; Khajoueinejad, N.; Benard, A.; Sengupta, M.; Herold, B.C.; Jacobs, W.R. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. Elife Sci. 2015, 4, 233-237.[CrossRef] [PubMed]
41. Norberg, P.; Kasubi, M.; Haarr, L.; Bergström, T.; Liljeqvist, J.-Å. Divergence and recombination of clinical herpes simplex virus type 2 isolates. J. Virol. 2007, 81, 13158-13167.[CrossRef] [PubMed]
42. Lal, H.; Cunningham, A.L.; Godeaux, O.; Chlibek, R.; Diez-Domingo, J.; Hwang, S.J.; Levin, M.J.; McElhaney, J.E.; Poder, A.; Puig-Barbera, J. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 2015, 372, 2087-2096.[CrossRef] [PubMed]